May 2026: Psychiatric Comorbidities in Substance Use Disorders: Sex-Based Differences in a National Real-World Clinical Sample
Dr. Eduardo Butelman (Icahn School of Medicine at Mount Sinai, New York) joins AJP Audio to discuss the varying incidence of psychiatric comorbidities across patients diagnosed with substance use diso...
1 Mai 30min
April 2026: Mobile Health for Alcohol Use Assessment: Longitudinal Effects of Breathalyzer Self-Monitoring in Everyday Contexts
Yang Lu, M.S., and Catharine E. Fairbairn, Ph.D. (University of Illinois, Urbana-Champaign) join AJP Audio to discuss the longitudinal effects of the use of personal alcohol breathalyzers in a natural...
1 Apr 35min
March 2026: Primary Prevention of PTSD Symptoms in Combat-Deploying Soldiers Using Attention Bias Modification: A Randomized Controlled Trial
Chelsea Dyan Gober Dykan, M.A. (Tel Aviv University, Israel), joins AJP Audio to discuss a study looking at two versions of attention bias modification with an eye towards a prophylactic impact on dev...
1 Mar 33min
February 2026: Doxycycline Use in Adolescent Psychiatric Patients and Risk of Schizophrenia: An Emulated Target Trial
Dr. Ian Kelleher (University of Edinburgh, Scotland) joins AJP Audio to discuss an emulated target trial looking at the prophylactic qualities of doxycycline, an antibiotic, in an adolescent populatio...
1 Feb 29min
Special Episode: 2025 Articles of Import and Impact
This special episode of AJP Audio brings together the editors of the American Journal Psychiatry and the AJP Residents' Journal to discuss important and impactful articles published in 2025. 00:39 ...
23 Jan 33min
January 2026: Reduced Threat-Related Neural Efficiency: A Possible Biomarker for Pediatric Anxiety Disorders
Dr. Julia Linke (University of Mainz, Germany) joins AJP Audio to discuss the use of neural efficiency, a measure of brain activity, as a potential biomarker in the treatment of children with anxiety ...
1 Jan 26min
December 2025: Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial
Dr. Suresh Durgam (Intra-Cellular Therapies, a Johnson & Johnson Company, Bedminster, NJ) joins AJP Audio to discuss a phase 3 randomized controlled trial looking at the use of the antipsychotic medic...
1 Des 202522min
November 2025: Contingency Management for Stimulant Use Disorder and Association With Mortality: A Cohort Study
Dr. Lara Coughlin (University of Michigan, Ann Arbor) joins AJP Audio to discuss a study looking the impact of contingency management on all cause mortality in patients with stimulant use disorder. Af...
1 Nov 202527min
